Auxilium biotech partners Swedish Orphan Biovitrum in long-term collaboration for development, supply and commercialization of XIAPEX.
XIAPEX is a novel, first-in-class biologic for the treatment of Dupuytren's contracture.
In addition to the biotech partners collaboration and co-development, work is on-going to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU.
Under the terms of the biotech partners collaboration agreement, Swedish Orphan Biovitrum will receive exclusive rights to commercialize XIAPEX for these two indications, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern & North African countries.
Under the terms of the biotech partners collaboration agreement, Auxilium will receive significant tiered double-digit royalties based on sales of XIAPEX in Swedish Orphan Biovitrum's territories, which will also cover payment for product supply.
Additionally, Swedish Orphan Biovitrum, a big biotech company, could make up to $40 million in potential sales milestone payments to Auxilium.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity